ATE304866T1 - Chelatorkonjugate mit verbesserten eigenschaften - Google Patents
Chelatorkonjugate mit verbesserten eigenschaftenInfo
- Publication number
- ATE304866T1 ATE304866T1 AT02745600T AT02745600T ATE304866T1 AT E304866 T1 ATE304866 T1 AT E304866T1 AT 02745600 T AT02745600 T AT 02745600T AT 02745600 T AT02745600 T AT 02745600T AT E304866 T1 ATE304866 T1 AT E304866T1
- Authority
- AT
- Austria
- Prior art keywords
- improved properties
- chelator conjugates
- radiometal
- conjugates
- chelator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0116815.2A GB0116815D0 (en) | 2001-07-10 | 2001-07-10 | Improved chelator conjugates |
| PCT/GB2002/003168 WO2003006070A2 (en) | 2001-07-10 | 2002-07-10 | Improved chelator conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304866T1 true ATE304866T1 (de) | 2005-10-15 |
Family
ID=9918227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02745600T ATE304866T1 (de) | 2001-07-10 | 2002-07-10 | Chelatorkonjugate mit verbesserten eigenschaften |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7597875B2 (de) |
| EP (1) | EP1404377B1 (de) |
| JP (1) | JP5015409B2 (de) |
| KR (1) | KR100892009B1 (de) |
| CN (4) | CN101537190A (de) |
| AT (1) | ATE304866T1 (de) |
| AU (1) | AU2002317317B2 (de) |
| BR (1) | BR0210965A (de) |
| CA (1) | CA2450690C (de) |
| DE (1) | DE60206272T2 (de) |
| DK (1) | DK1404377T3 (de) |
| ES (1) | ES2250671T3 (de) |
| GB (1) | GB0116815D0 (de) |
| HU (1) | HU228850B1 (de) |
| IL (1) | IL159388A0 (de) |
| MX (1) | MXPA04000210A (de) |
| NO (1) | NO334093B1 (de) |
| RU (1) | RU2298012C2 (de) |
| WO (1) | WO2003006070A2 (de) |
| ZA (1) | ZA200400143B (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002239655A1 (en) | 2001-01-05 | 2002-07-16 | Duke University | Contrast enhancement agent for magnetic resonance imaging |
| ES2719088T3 (es) * | 2001-07-10 | 2019-07-08 | Ge Healthcare Ltd | Compuestos con base peptídica para localizar receptores de integrina |
| NO20030115D0 (no) | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
| JP2007510643A (ja) * | 2003-11-06 | 2007-04-26 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 医薬化合物 |
| GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
| EP1699494A2 (de) * | 2003-11-24 | 2006-09-13 | GE Healthcare AS | Kontrastmittel-darstellung angiotensin-ii-rezeptoren |
| EP1729823B1 (de) * | 2004-03-04 | 2009-11-04 | GE Healthcare AS | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie |
| BRPI0518328A2 (pt) | 2004-11-22 | 2008-11-11 | Ge Healthcare As | agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica |
| GB0427392D0 (en) * | 2004-12-15 | 2005-01-19 | Amersham Plc | Stabilised 99mTc compositions |
| WO2006131803A2 (en) * | 2005-06-08 | 2006-12-14 | Ge Healthcare Limited | Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical carbonylation |
| GB0515974D0 (en) * | 2005-08-03 | 2005-09-07 | Ge Healthcare Ltd | Compounds and imaging methods |
| WO2007094683A1 (en) | 2006-02-15 | 2007-08-23 | Ge Healthcare As | Contrast agents |
| US7943117B2 (en) * | 2006-06-08 | 2011-05-17 | Atomic Energy Council—Institute of Nuclear Research | Method for testing radiochemical purity of Tc-99m-TRODAT-1 |
| MX2009006028A (es) * | 2006-12-11 | 2009-06-17 | Ge Healthcare As | Compuestos basados en peptido radiomarcado y usos de los mismos. |
| ES2712881T3 (es) | 2008-12-02 | 2019-05-16 | Univ Melbourne | Conjugados macrocíclicos que contienen nitrógeno como radiofármacos |
| GB0922014D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
| EP2598175B1 (de) * | 2010-07-27 | 2020-05-20 | Serac Healthcare Limited | Radiopharmazeutische zusammensetzungen |
| GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
| GB201110767D0 (en) | 2011-06-24 | 2011-08-10 | Ge Healthcare Ltd | Infection imaging |
| US20130195756A1 (en) | 2012-01-31 | 2013-08-01 | General Electric Company | 99mTc IMAGING AGENTS AND METHODS OF USE |
| WO2014126902A1 (en) * | 2013-02-15 | 2014-08-21 | Thomas Jefferson University | Kit for tumor imaging |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
| ES2824674T3 (es) | 2014-03-19 | 2021-05-13 | Univ Zuerich | Agentes quelantes bifuncionales multidentados para la complejación de radionúclidos en el diagnóstico y la terapia |
| CN112840025A (zh) * | 2018-05-08 | 2021-05-25 | 迈阿密大学 | 用于将治疗性核酸递送到组织的材料方法 |
| EP3793619A4 (de) | 2018-05-16 | 2022-01-12 | Emory University | Styrylbenzothiazolderivate und ihre verwendung in der bilderzeugung |
| CN111548275A (zh) * | 2020-05-27 | 2020-08-18 | 龙曦宁(上海)医药科技有限公司 | 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1588978A (en) * | 1977-07-19 | 1981-05-07 | Ici Ltd | Coating processes |
| DE3930674A1 (de) * | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
| US5849261A (en) * | 1991-02-08 | 1998-12-15 | Diatide, Inc. | Radiolabeled vasoactive intestinal peptides for diagnosis and therapy |
| US5808091A (en) * | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
| US5997843A (en) * | 1993-08-04 | 1999-12-07 | Amersham International Plc | Radiometal complexes that localise in hypoxic tissue |
| DE69501981T2 (de) * | 1994-01-12 | 1998-12-10 | Bracco International B.V., Amsterdam | Liganden und deren metallkomplexe |
| CA2179990A1 (en) * | 1994-01-12 | 1995-07-20 | Gary Robert Bower | Biological targeting agents |
| DE69937996T2 (de) | 1998-05-15 | 2009-01-02 | Ge Healthcare Ltd., Little Chalfont | Markierte glutamin- und lysinanaloge |
| US6783711B2 (en) * | 2000-05-23 | 2004-08-31 | Ge Osmonics, Inc. | Process for preparing a sulfonamide polymer matrix |
| JP4009198B2 (ja) * | 2001-03-08 | 2007-11-14 | 松下電器産業株式会社 | インクジェット記録用インク、該インクの製造方法、並びに該インクを備えたインクカートリッジ及び記録装置 |
-
2001
- 2001-07-10 GB GBGB0116815.2A patent/GB0116815D0/en not_active Ceased
-
2002
- 2002-07-08 CN CNA200910127855XA patent/CN101537190A/zh active Pending
- 2002-07-08 CN CNA2008102133680A patent/CN101538313A/zh active Pending
- 2002-07-10 HU HU0401265A patent/HU228850B1/hu not_active IP Right Cessation
- 2002-07-10 EP EP02745600A patent/EP1404377B1/de not_active Expired - Lifetime
- 2002-07-10 JP JP2003511875A patent/JP5015409B2/ja not_active Expired - Lifetime
- 2002-07-10 KR KR1020047000303A patent/KR100892009B1/ko not_active Expired - Fee Related
- 2002-07-10 CN CN2009102035216A patent/CN101607913B/zh not_active Expired - Fee Related
- 2002-07-10 IL IL15938802A patent/IL159388A0/xx unknown
- 2002-07-10 AT AT02745600T patent/ATE304866T1/de active
- 2002-07-10 US US10/483,455 patent/US7597875B2/en not_active Expired - Lifetime
- 2002-07-10 ES ES02745600T patent/ES2250671T3/es not_active Expired - Lifetime
- 2002-07-10 DK DK02745600T patent/DK1404377T3/da active
- 2002-07-10 BR BR0210965-4A patent/BR0210965A/pt active Search and Examination
- 2002-07-10 CN CNB028140087A patent/CN100509061C/zh not_active Expired - Fee Related
- 2002-07-10 RU RU2003137592/04A patent/RU2298012C2/ru not_active IP Right Cessation
- 2002-07-10 DE DE60206272T patent/DE60206272T2/de not_active Expired - Lifetime
- 2002-07-10 MX MXPA04000210A patent/MXPA04000210A/es active IP Right Grant
- 2002-07-10 CA CA002450690A patent/CA2450690C/en not_active Expired - Lifetime
- 2002-07-10 WO PCT/GB2002/003168 patent/WO2003006070A2/en not_active Ceased
- 2002-07-10 AU AU2002317317A patent/AU2002317317B2/en not_active Ceased
-
2003
- 2003-12-16 NO NO20035597A patent/NO334093B1/no not_active IP Right Cessation
-
2004
- 2004-01-08 ZA ZA200400143A patent/ZA200400143B/xx unknown
-
2009
- 2009-10-01 US US12/571,508 patent/US8852550B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60206272D1 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
| MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
| ECSP034600A (es) | Compuestos de lactama | |
| MXPA05009682A (es) | Metodos de radiofluorinacion de vectores biologicamente activos. | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| DE60213276D1 (de) | 1,2,4-thiadiazoliumverbindungen als melanocortinrezeptor-modulatoren | |
| BR0216099B1 (pt) | "conjunto de desgaste". | |
| DE50202328D1 (de) | Amidofunktionelle aminopolydiorganosiloxane | |
| IL181529A (en) | A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug | |
| TR200003389T2 (tr) | 2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri. | |
| DE60210598D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
| TR199901017A2 (xx) | B�cek ilac� terkibi. | |
| DE10108995A1 (de) | Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren | |
| DE60213084D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
| ID27733A (id) | Metoksiminofenilasetamida | |
| ITTO20020747A1 (it) | Composizione. | |
| NO20021429L (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
| ITMI20030827A1 (it) | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. | |
| ITTO20020745A1 (it) | Composizione. | |
| FR2845696B1 (fr) | Non-tisses microfibreux, complexes les incorporant, preparations | |
| TR200102093T2 (tr) | Organ koruyucu çözeltiler | |
| UA50172A (uk) | Засіб для лікування мігрені | |
| UA115859C2 (uk) | Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить | |
| MY143246A (en) | Triazole substituted aminobensophenone compounds | |
| ITTO20020746A1 (it) | Composizione. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1404377 Country of ref document: EP |